- Home
- LEGH vs OMER Comparison
LEGH vs OMER Comparison
Compare LEGH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- OMER
- Stock Information
- Founded
- LEGH 2005
- OMER 1994
- Country
- LEGH United States
- OMER United States
- Employees
- LEGH N/A
- OMER N/A
- Industry
- LEGH Homebuilding
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- OMER Health Care
- Exchange
- LEGH Nasdaq
- OMER Nasdaq
- Market Cap
- LEGH 601.1M
- OMER 530.2M
- IPO Year
- LEGH 2018
- OMER 2009
- Fundamental
- Price
- LEGH $25.90
- OMER $9.21
- Analyst Decision
- LEGH Buy
- OMER Buy
- Analyst Count
- LEGH 2
- OMER 4
- Target Price
- LEGH $29.00
- OMER $22.50
- AVG Volume (30 Days)
- LEGH 59.5K
- OMER 509.4K
- Earning Date
- LEGH 03-14-2025
- OMER 03-31-2025
- Dividend Yield
- LEGH N/A
- OMER N/A
- EPS Growth
- LEGH N/A
- OMER N/A
- EPS
- LEGH 2.18
- OMER N/A
- Revenue
- LEGH $163,718,000.00
- OMER N/A
- Revenue This Year
- LEGH N/A
- OMER N/A
- Revenue Next Year
- LEGH $8.19
- OMER N/A
- P/E Ratio
- LEGH $11.66
- OMER N/A
- Revenue Growth
- LEGH N/A
- OMER N/A
- 52 Week Low
- LEGH $19.42
- OMER $2.61
- 52 Week High
- LEGH $29.31
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- LEGH 58.76
- OMER 49.57
- Support Level
- LEGH $24.46
- OMER $8.28
- Resistance Level
- LEGH $26.16
- OMER $9.08
- Average True Range (ATR)
- LEGH 0.73
- OMER 0.55
- MACD
- LEGH 0.12
- OMER -0.02
- Stochastic Oscillator
- LEGH 77.01
- OMER 56.45
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to customers to facilitate the sale of homes.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.